An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy
American Thoracic Society |
 |
| California TB Risk Assessments |
 |
Confidential Morbidity Report – Tuberculosis
County of Orange, Health Care Agency, Public Health Services |
|
Diagnosis of Tuberculosis in Adults and Children, 2017 Guidelines
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America |
|
Diagnostic Standards and Classification of Tuberculosis in Adults and Children
American Thoracic Society |
|
Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, 3rd Edition
Curry International Tuberculosis Center |
|
Interferon Gamma Release Assays (IGRA's)
Centers for Disease Control & Prevention |
|
Latent Tuberculosis Infection: A Guide for Primary Healthcare Providers
Centers for Disease Control & Prevention |
|
Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis
Centers for Disease Control & Prevention |
|
| Sample LTBI Treatment Record Book |
|
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection
Centers for Disease Control & Prevention, MMWR; vol. 49/No. RR-6 |
|
| Three Months Once Weekly Isoniazid Plus Rifapentine (3HP) Trifold Pamphlet |
|
Treatment of Tuberculosis
American Thoracic Society |
|
Treatment of Drug-Susceptible Tuberculosis, 2016 Guidelines
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America |
|
